secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-022266
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics suspends ATM equity offering program
-------------------------------------------------------

- Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.
- No further sales of common stock under the Sales Agreement until a new prospectus supplement is filed.
- Sales Agreement remains in full force and effect; suspension does not terminate it.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024022266/0000950170-24-022266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024022266/janx-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer